NCT07524634 2026-04-13
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT07215494 2025-10-10
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Peking University First Hospital
Phase NA Not yet recruiting
NCT07055724 2025-07-09
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
Phase 2 Not yet recruiting
NCT06769555 2025-01-10
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting